Andrzej Rostek
Syndax Pharmaceuticals (NASDAQ:SNDX) said the FDA has granted Priority Review status for its New Drug Application for revumenib in the treatment of relapsed/refractory KMT2Ar acute leukemia.
The drug was previously granted Fast Track and Breakthrough Therapy status by the agency for the indication.
The FDA set a target action date of Sept. 26 for the application.
More on Syndax Pharmaceuticals
- Syndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
- Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript
- FDA accepts Incyte application for graft-versus-host disease drug
- Barron’s cites cancer and weight loss plays for biotech M&A
- Seeking Alpha’s Quant Rating on Syndax Pharmaceuticals